Patents Examined by Susanna Moore
  • Patent number: 12012386
    Abstract: The invention relates to new olaparib oxalic acid cocrystals. The olaparib oxalic acid cocrystals vary in ratio from 1:1 to 2:3 olaparib:oxalic acid. In particular, the invention relates to a 2:3 olaparib oxalic acid cocrystal, a 1:1 olaparib oxalic acid cocrystal, and a 2:1 olaparib oxalic acid cocrystal. The invention also relates to pharmaceutical compositions containing an olaparib oxalic acid cocrystal of the invention and a pharmaceutically acceptable carrier. The olaparib oxalic acid cocrystals of the invention Got may be useful for the treatment of diseases that benefit from inhibition of poly (ADP-ribose) polymerase (PARP). These include cancer, fibrosis, inflammatory conditions (e.g. asthma, colitis, arthritis), neurological diseases (e.g. neurodegeneration, neurotrauma, stroke), cardiovascular conditions, ophthalmic degenerative diseases, vascular diseases (e.g. diabetic complications, atherosclerosis), and various forms of critical illness (e.g. septic shock, ALI, acute liver failure).
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: June 18, 2024
    Assignee: NUFORMIX TECHNOLOGIES LIMITED
    Inventors: Joanne Holland, Alex Eberlin, Christopher Frampton
  • Patent number: 12006328
    Abstract: The disclosure relates thieno[2,3-d]pyrimidin-4-one derivatives as modulators of NMDA receptors and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing conditions related to cognition, typically prevention or treatment of neurological conditions related to the NMDA receptor.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: June 11, 2024
    Assignee: Emory University
    Inventors: Stephen F. Traynelis, Lanny S. Liebeskind, Dennis C. Liotta, Ethel C. Garnier-Amblard, PavanKumar Reddy Gangireddy
  • Patent number: 12004512
    Abstract: Synthesis of a compound N-[(4,6-dimethylpyrimidin-2-yl)carbamothioyl]pyridine-3-carboxamide and its use as an insecticidal agent.
    Type: Grant
    Filed: October 13, 2023
    Date of Patent: June 11, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Mohamed A. Gad
  • Patent number: 11998534
    Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a GPX4-mediated disorder, disease, or condition in a subject with a GPX4 inhibitor and an anticancer agent. Also provided herein are methods of inducing ferroptosis in a cell or inhibiting the growth of a cell with a GPX4 inhibitor and an anticancer agent.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: June 4, 2024
    Assignee: Eubulus Biotherapeutics Inc.
    Inventor: Sheldon Cao
  • Patent number: 11993614
    Abstract: The present invention relates to novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I), wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: May 28, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Edward Charles Lawson, Lieven Meerpoel, Vineet Pande, Marcus Cornelius Bernardus Catharina Parade, Wim Bert Griet Schepens, Weimei Sun, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye
  • Patent number: 11992494
    Abstract: Cyclopentathiophene carboxamides of formula (I), wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of formula (I) can be used in methods for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.
    Type: Grant
    Filed: December 19, 2022
    Date of Patent: May 28, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Ferenc Kontes, Christofer Siegfried Tautermann, Dieter Wiedenmayer, Marina Kristina Willwacher
  • Patent number: 11986485
    Abstract: Disclosed herein are compositions and methods for delivering compositions to a subject in need of treatment for epilepsy. The disclosed compositions are orally delivered. Further disclosed are kits comprising the disclosed compositions as part of a method of delivering cannabidiol and CBD-containing compositions to subjects in need of treatment for epilepsy.
    Type: Grant
    Filed: July 24, 2023
    Date of Patent: May 21, 2024
    Assignee: POVIVA CORP
    Inventors: John Docherty, Christopher Andrew Bunka
  • Patent number: 11986486
    Abstract: Provided herein are novel ready-to-use bortezomib formulations, methods of preparing, and methods of using the same.
    Type: Grant
    Filed: November 1, 2021
    Date of Patent: May 21, 2024
    Assignee: SPES PHARMACEUTICALS INC.
    Inventor: Jianwei Yu
  • Patent number: 11986528
    Abstract: The invention concerns the use, as a pharmaceutical or cosmetic excipient, of a composition which is solid at ambient temperature and in the form of individualized particles, said composition comprising: lauroyl macrogolglyceride, polyethylene glycol.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: May 21, 2024
    Assignee: GATTEFOSSE SAS
    Inventors: Amandine Forest, Jean-David Rodier
  • Patent number: 11981645
    Abstract: A N?-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide compound, its synthesis, and its use as an anti-microbial agent.
    Type: Grant
    Filed: October 10, 2023
    Date of Patent: May 14, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Mohamed Gouda, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11974570
    Abstract: Synthesis of a compound 1,3-bis(naphthalen-1-yloxy)propan-2-one and its use as an insecticidal agent.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: May 7, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer, Mohamed A. Gad
  • Patent number: 11975106
    Abstract: A method for treating a viral infection of a mammalian subject that comprises administering a virus-inhibiting amount of a halogenated xanthene, a pharmaceutically acceptable salt, an alkyl ester or amide or aromatic ester or amide derivative thereof as disclosed within, to that mammalian subject. A method of inducing a type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene as discussed above, and an immunogen to which that response is to be enhanced.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: May 7, 2024
    Assignees: Provectus Pharmatech, Inc., UTI Limited Partnership
    Inventors: Aru Narendran, Edward V. Pershing, Dominic Rodrigues, Bruce Horowitz, Eric A. Wachter
  • Patent number: 11964993
    Abstract: The present invention relates to a process for the preparation of crystalline Bortezomib of formula (I) and its pharmaceutical acceptable salts thereof. The present invention relates to a process for the preparation of highly pure crystalline Bortezomib (I).
    Type: Grant
    Filed: June 14, 2022
    Date of Patent: April 23, 2024
    Assignee: SHILPA PHARMA LIFESCIENCES LIMITED
    Inventors: Rafiuddin Dr, Ananta Naga Kanaka Durga Reddy Guntaka
  • Patent number: 11964971
    Abstract: Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, pharmaceutical compositions comprising the same, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: April 23, 2024
    Assignee: SKYHAWK THERAPEUTICS, INC.
    Inventors: Michael Luzzio, Brian Lucas, Tiansheng Wang, Jun Feng
  • Patent number: 11958865
    Abstract: The present invention is directed to compounds of formula IIa These compounds are considered useful for the treatment of diseases associated with leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease. Furthermore, the invention relates to pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: September 14, 2023
    Date of Patent: April 16, 2024
    Assignee: H. Lundbeck A/S
    Inventors: Thomas Jensen, Thomas Andersen, Mikkel Jessing, Jacob Nielsen, Henrik Daver, Christopher Richard Jones
  • Patent number: 11945797
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30).
    Type: Grant
    Filed: February 18, 2022
    Date of Patent: April 2, 2024
    Assignee: Mission Therapeutics Limited
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Michael David Woodrow
  • Patent number: 11938182
    Abstract: A method of inducing a Type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the Type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene, and an immunogen to which that response is to be enhanced. A mammalian HX compound-adjuvanted vaccine composition that contains an immunogen present in a vaccine-effective amount along with an adjuvant-effective amount of a halogenated xanthene (HX) compound and one or more excipients present at about 0.001% by weight to 10% by weight of the vaccine composition dissolved or dispersed in a pharmaceutically acceptable diluent.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: March 26, 2024
    Assignees: Provectus Pharmatech, Inc., UTI Limited Partnership
    Inventors: Aru Narendran, Dominic Rodrigues, Edward V. Pershing, Bruce Horowitz
  • Patent number: 11930815
    Abstract: A 3,3?-(piperazine-1,4-diyl)bis(1-(naphthalen-2-yloxy)propan-2-ol) compound, its synthesis, and its use as an insecticidal agent.
    Type: Grant
    Filed: August 29, 2023
    Date of Patent: March 19, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhaim Ahmed, Mohamed A. Gad
  • Patent number: 11932646
    Abstract: The present disclosure provides novel heteroaryl compounds of formula (VII). Such compounds are useful for the treatment of cancers.
    Type: Grant
    Filed: January 12, 2022
    Date of Patent: March 19, 2024
    Assignees: THE SCRIPPS RESEARCH INSTITUTE, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Jianming Zhang, Barun Okram, Xianming Deng, Jae Won Chang, Amy Wojciechowski
  • Patent number: 11912718
    Abstract: The present invention provides solid forms of compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, methods of producing the same, and methods of using the same in the treatment of ACC-mediated diseases.
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: February 27, 2024
    Assignee: Gilead Apollo, LLC
    Inventor: Xiaowei Yang